Peptide Sciences Peptides: The Catalog, Documented

The Peptide Sciences catalog was the tier's reference assortment: a broad research-peptide repertoire — the classic investigation compounds, recovery-reputation sequences, cosmetic-interest peptides — capped, in its final period, by the GLP-1 family that came to define the era: semaglutide, retatrutide (see the retatrutide page), and tirzepatide-adjacent entries. The catalog pages carried the company's documentation package by default, which is what "Peptide Sciences peptides" meant to its customers: vials with paperwork.

The documentation package is the part worth preserving as a market artifact, because it became the informal standard: lot-linked COA with method and wavelength stated, product-level purity claims tied to actual batch analysis, and periodic third-party summaries — the record reconstructed on our review page, and the standard this site applies to every seller (see best quality peptides).

Pricing ran at the premium end of the research tier — a documentation premium in effect, the same trade our catalog peptides page maps between price and paperwork — and GLP-1-family pricing anchored to the drug-price logic analyzed on peptide price. The company profile and its closure are documented on their own pages: company, shutdown.

The afterlife is the cautionary part: the catalog's demand persists as search volume, and post-closure that demand is harvested by imitator domains and succession claims — the website page documents the pattern. No original-catalog product is purchasable from the original source; anything sold today under the name is a different seller's material, evaluated (if at all) by different documents.

Step 1 — fix the evidence class. Every claim about Peptide Sciences Peptides belongs to one class in the table above — archived listing, archived COA, registry record, dated community thread, or undated recollection. Classify first; a strong claim on weak evidence is still a weak claim. Step 2 — date the snapshot. The company's record spans roughly a decade, and documentation habits, catalog, and pricing all changed over that period. A statement true of the 2021–2023 catalog may not describe the earlier years; every conclusion in this hub carries the capture date it rests on, and yours should too. Step 3 — separate the company from its aftermarket. Anything asserted by imitator domains or successors is a claim about the present, not evidence about the original — continuity must be shown in documents, never assumed from a name. The full research method is in the peptide sciences research hub hub; Peptide Sciences Website applies the same evidence classes to a different question.

Researching a closed company means grading what survived. This table ranks the evidence types behind every claim in this hub, from strongest to weakest, so each statement can be checked against its source class.

Table: Parameter comparison: evidence types in the company record — apply it to any page in this cluster.